drugs for ischaemic heart disease Flashcards
drugs known to improve prognosis of angina
aspirin
clopidogrel
statins
comparison of percutaneous transarterial coronary arteriography vs alteplase fibrinolysis
N=1572 with MI PTCA or alteplase
No difference in immediate mortality
PTCA better for preventing recurrence
fibrinolysis-higher bleed rate
the most important thing to remember in acute MI patients
that the speed of diagnosis and treatment has a significant effect on mortality. a door to needle time of under 30 mins has an in hospital mortality of 2%. over 45mins has a mortality of 7%.
Treatment of MI (London)
1 - Ambulance
Diagnosis
Aspirin
2 - Hospital
Primary angioplasty
Stent
Clopidogrel (depending on stent)
Acute chest pain at rest decision flow chart
proven to reduce mortality
1 - Typical history, ST elevation?
if yes then diagnosis MI - Defib available Oxygen Diamorphine/metaclopramide Aspirin 300mg # PTCA # b-blocker # ACE inhibitor # Statin # Nitrate for pain (clopidogrel-probably not)
if no then:
2 - Hx, ECG and trop T?
if yes then NSTEMI/ UA (unstable angina) - Defib available Aspirin 300mg # b-blocker Nitrate infusion for pain LMW heparin (or UF) # Statin # GpIIb/IIIa receptor blocker if high-risk # ?coronary angiogram/PTCA
if no then not coronary pain
what is ACS
acute coronary syndrome - contains acute MI, NSTEMI and unstable angina.
NSTEMI is diagnosed with a raised trop T where as Unstable angina is a clinical diagnosis.
Approximately 12% of patients admitted to hospital with unstable angina/NSTEMI suffer MI within 2 weeks
use of angiography in stable angina
gold standard
disease patterns influence prognosis
eg LMS, 3VD, 2VD/LMS may benefit from revascularisation BUT morbidity 1/1000, mortality 1/10 000 RELATED TO PROCEDURE NOT DISEASE
Therefore patients are stratified prior to angiography with non-invasive investigations:
positive ETT at low stress
failure of maximal therapy
post MI angina
name 2 drugs that a stent might elute
paclitaxel
sacrolimus
Stents-bare metal vs drug eluting
Billion dollar industry
Very few good trials
No evidence of superiority (but $$$)
Next “big thing”-dissolving stents